(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged BioNTech, BNT211, BNT325, cancer therapy, CAR-T, ESMO Congress 2023, ex-vivo T cell therapies, Prof. Özlem Türeci
The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University of Zurich researchers have announced a study that is showing how hematopoietic stem cells from a healthy donor can help … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute leukemia, Acute myeloid leukemia, Alexander Simonis, AML, Antonia M. Müller, blood stem cells, bone marrow, Burkhard Becher, C. Matthias Wilk, Cancer, cancerous hematopoietic stem cells, CAR-T, chemotherapy, Chiara F. Magnani, Christian Münz, Dario Neri, Donal McHugh, ETH Zurich, genetic modification, hematology, Hematopoietic stem cells, immunotherapy, Jonathan D. Kiefer, Juliane Friemel, leukemia, Maries van den Broek, Markus G. Manz, Markus Manz, Nicolás Nuñez, Norman F. Russkamp, oncology, platelets, radiotherapy, red blood cells, Renier Myburgh, Surema Pfister, transplant, University Hospital Zurich, University of Zurich, white blood cells
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged CAR-T, FDA, Kymriah, leukemia, Liz Barrett, lymphoma, Novartis, oncology, Stephen J. Schuster MD, tisagenlecleucel
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
